Mylan Inc. (NASDAQ:MYL) one of the giants in the manufacture of generics is reported to have received a setback on its plans to acquire Swedish Pharmaceutical giant Meda AB, valued at $4.5 billion. Mylan Inc. (NASDAQ:MYL) shares after opening at $48.74 moved to $48.92 on last trade day and at the end of the day closed at $47.07. Company price to sales ratio in past twelve months was calculated as 2.53 and price to cash ratio as 60.10. Mylan Inc. (NASDAQ:MYL) showed a negative weekly performance of -5.60%.
Ariad Pharmaceuticals (NASDAQ:ARIA) has been given an average recommendation of “Hold” by the twenty-four analysts that are currently covering the stock, American Banking & Market News reports. Three investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and six have assigned a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $7.29. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares fell -4.74% in last trading session and ended the day on $7.23. ARIA return on equity ratio is recorded as -98.50% and its return on assets is -65.80%. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) yearly performance is -59.94%.
Boston Scientific Corporation (NYSE:BSX) has enrolled the first patient in a new registry to evaluate clinical outcomes and the economic value of the Vercise™ Deep Brain Stimulation (DBS) System in patients with Parkinson’s disease. Boston Scientific Corporation (NYSE:BSX) shares moved down -4.51% in last trading session and was closed at $12.93, while trading in range of $12.88 – $13.59. Boston Scientific Corporation (NYSE:BSX) year to date (YTD) performance is 7.57%.
MannKind Corporation (NASDAQ:MNKD) shares have been down recently owing to the FDA’s decision to extend the PDUFA date for Afrezza to July 15, 2014. MannKind Corporation (NASDAQ:MNKD) weekly performance is -1.15%. On last trading day company shares ended up $6.85. MannKind Corporation (NASDAQ:MNKD) distance from 50-day simple moving average (SMA50) is 18.82%. Analysts mean target price for the company is $7.14.
Leave a Reply